Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Mental Health and Electronic Health Records

The mental and behavioral health industry is at an exciting crossroads. No longer an afterthought to traditional healthcare, this area of medical specialization is finally being recognized as an integral facet of a person’s health and well-being. In fact, most businesses today encourage employees to seek treatment early before certain conditions spiral into larger problems,…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

The mental and behavioral health industry is at an exciting crossroads. No longer an afterthought to traditional healthcare, this area of medical specialization is finally being recognized as an integral facet of a person’s health and well-being. In fact, most businesses today encourage employees to seek treatment early before certain conditions spiral into larger problems, with more and more health plans including expanded provisions for mental health. Further, local governments are extending similar support for mental health-related issues via public awareness campaigns.

Study the numbers, and you’ll arrive at just one conclusion: mental and behavioral health is a growing industry, with plenty of growth still to come.

Preparing for Growth

Recent studies suggest that 1 in 5 adults living in the United States has a mental health condition. That’s more than 40 million people in need of a provider. Of these 40 million people, however, only about 40% of them are currently seeking care. Why, you ask? Consider this: as busy as most clinics are (and many of them are extraordinarily busy), current business models impede their capability of rendering care to more patients, restricting patient loads to less than half of the number of people who need their services. And going forward, the demand for mental health care will only increase—the fact that millennials seem more aware and more open to the benefits of mental health care than older generations supports this prediction.

But how will providers keep up with this growth? How will they maintain efficiency in the office, stay up to speed with treatment plans, and communicate with fellow staff while still offering their patients the comprehensive, compassionate care they deserve, all without burning out?

Enter behavioral health EHR’s.

Choosing the Right EHR

If you’re a mental health provider, an effective, easy-to-use, scalable EHR makes your life easier. It’s as simple as that. But if you’ve shopped for an EHR before, you know how many different options the market offers. You know, too, that many of them are bulky—resistant to growth. Maybe you’ve convinced yourself that these unwieldy platforms are just part of the price of keeping yourself and your practice in business. The good news is: it doesn’t have to be that way.

The right behavioral health EHR will be user-friendly, secure, 100% reliable, and will integrate easily, seamlessly with your practice needs and workflows.

Enter ChartLogic’s Lite EHR.

Prepare for Growth with ChartLogic

Purposely-built for mental and behavioral health practices in mind, ChartLogic EHR Lite is the perfect fit. EHR Lite enables practices to save time and money while expanding their patient base and meeting the needs and growth of mental and behavioral health specialists.

Prepare and future-proof your practice for the increased demands of the growing mental health industry! Learn more about ChartLogic’s EHR solutions by visiting our website, and schedule a demo with one of our experts today.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended AstraZeneca and Daiichi Sankyo’s Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly is investing $6.5 billion in a Houston manufacturing facility set to open around 2030, primarily to scale production of Foundayo, its oral GLP-1 treatment. The project signals a broader shift in U.S. pharmaceutical manufacturing reshoring and underscores the supply chain challenge of forecasting demand and building capacity years in advance for breakthrough therapeutics.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain: Lilly's CEO noted that one-third of new GLP-1 pill patients are now choosing Foundayo, illustrating fast-moving market share shifts that complicate production planning years in advance
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

Waiting for perfectly clean data is stalling healthcare AI, not protecting it

Healthcare organizations often delay AI initiatives waiting for perfectly clean data, but this assumption no longer holds: reliable subsets and synthetic data allow projects to start now while data work continues in parallel. Success requires starting with business outcomes rather than technology capabilities, and embedding governance in product strategy before implementation, not after.

  • 01Waiting for 100% clean data is effectively a decision never to start; hospital AI projects can begin on reliable data subsets while quality work continues in parallel.
  • 02Frame AI decisions around business outcomes (revenue growth, cost reduction, competitive advantage, new products, or ecosystem influence) rather than asking what AI can do.
  • 03Governance should be part of product strategy before design or purchase, especially as agentic AI takes actions—such as handling many revenue-cycle denials—while routing the rest to humans.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512